Baker McKenzie Advises a Consortium led by SPE Capital, and included EBRD, Proparco and BIO on their Investment in Leading Ophthalmic Pharmaceutical Manufacturer

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

Not stated

What the figure measures

Not stated

Client

Not stated

Counterparties

SPE Capital (Investor)
European Bank for Reconstruction and Development (EBRD) (Investor)
Société de Promotion et de Participation pour la Coopération Économique (Proparco) (Investor)
Belgian Investment Company for Developing Countries (BIO) (Investor)
Orchidia Pharmaceutical Industries S.A.E. (Target)